Compare DEC & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DEC | ANL |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.4M | 998.8M |
| IPO Year | 2022 | 2022 |
| Metric | DEC | ANL |
|---|---|---|
| Price | $14.47 | $10.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $20.43 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 545.8K | 319.9K |
| Earning Date | 11-04-2026 | 08-14-2026 |
| Dividend Yield | ★ 7.90% | N/A |
| EPS Growth | ★ 311.06 | N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $1,829,142,000.00 | N/A |
| Revenue This Year | $24.84 | $243.83 |
| Revenue Next Year | $33.22 | N/A |
| P/E Ratio | $12.89 | ★ N/A |
| Revenue Growth | ★ 141.54 | N/A |
| 52 Week Low | $12.35 | $0.88 |
| 52 Week High | $18.90 | $17.25 |
| Indicator | DEC | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 36.44 |
| Support Level | $12.48 | $8.96 |
| Resistance Level | $14.95 | $12.49 |
| Average True Range (ATR) | 0.40 | 1.30 |
| MACD | 0.05 | -0.29 |
| Stochastic Oscillator | 60.87 | 5.98 |
Diversified Energy Co engaged in the production, transportation, and marketing of natural gas, NGLs, and oil, managing a diversified portfolio of mature, long-life assets located across the United States. The company derives revenues from the sale of oil, natural gas and natural gas liquids.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.